home / stock / crbu / crbu news

CRBU News and Press, Caribou Biosciences Inc. From 04/04/23

Stock Information
Company Name: Caribou Biosciences Inc.
Stock Symbol: CRBU
Market: NASDAQ
Website: cariboubio.com
Menu
CRBU CRBU Quote CRBU Short CRBU News CRBU Articles CRBU Message Board
Get CRBU Alerts

News, Short Squeeze, Breakout and More Instantly...
CRBU - Caribou stock pops on FDA fast track tag for blood cancer therapy CB-011

2023-04-04 08:58:11 ET The U.S. Food and Drug Administration (FDA) granted fast track designation to Caribou Biosciences' ( NASDAQ: CRBU ) allogeneic CAR-T cell therapy CB-011 to treat relapsed or refractory multiple myeloma (r/r MM). CB-011 is being evaluated in a phase 1 tri...
CRBU - Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma

-- CaMMouflage Phase 1 trial for CB-011 enrolling patients with r/r MM at dose level 1 -- BERKELEY, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the U.S. Fo...

CRBU - Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

-- CB-011 is designed to improve antitumor activity by cloaking the allogeneic CAR-T cells from immune-mediated rejection -- -- CB-011 is Caribou’s second program to enter the clinic from its off-the-shelf CAR-T cell therapy platform -- BERKELEY, Calif., March 29, 2023 (GLO...

CRBU - Caribou Biosciences Initiates Dose Expansion Portion of CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients

-- CB-010 is the first allogeneic CAR-T cell therapy, to Caribou’s knowledge, to be evaluated clinically in second-line LBCL patients -- -- Next ANTLER update planned for H2 2023 -- BERKELEY, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU...
CRBU - DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders Of a Lead Plaintiff Deadline of April 11, 2023 in Caribou Lawsuit - CRBU

New York, New York--(Newsfile Corp. - March 23, 2023) - Levi & Korsinsky, LLP notifies investors in Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU) of a class action securities lawsuit. The lawsuit on behalf of Caribou investors has been commenced in the the United St...

CRBU - DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 11, 2023 in Caribou Lawsuit - CRBU

New York, New York--(Newsfile Corp. - March 13, 2023) - Levi & Korsinsky, LLP notifies investors in Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU) of a class action securities lawsuit. The lawsuit on behalf of Caribou investors has been commenced in the the United St...

CRBU - Caribou Bioscience GAAP EPS of -$0.44 beats by $0.02, revenue of $3.7M beats by $0.63M

2023-03-10 03:33:29 ET Caribou Bioscience press release ( NASDAQ: CRBU ): Q4 GAAP EPS of -$0.44 beats by $0.02 . Revenue of $3.7M (+44.5% Y/Y) beats by $0.63M . Caribou had $317.0M in cash, cash equivalents, and marketable securities as of December 31, 2022, co...
CRBU - Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

-- CB-010 ANTLER Phase 1 trial in r/r B-NHL ongoing with update planned for H2 2023 -- -- CB-011 CaMMouflage Phase 1 trial in r/r MM recruiting patients at dose level 1 -- -- CB-012 IND-enabling studies initiated; IND submission in r/r AML planned for H2 2023 -- -- $317.0 ...

CRBU - Caribou Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference

BERKELEY, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, is scheduled to participate in...

CRBU - Lawsuit filed for Investors with substantial Losses in Caribou Biosciences, Inc. (NASDAQ: CRBU) shares announced by the Shareholders Foundation

SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in Caribou Biosciences, Inc. (NASDAQ: CRBU) shares. Investors who suffered losses in excess of $200,000 with shares of Caribou Biosciences, Inc. (NASDAQ: CRB...
Previous 10 Next 10